Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer

Study limitation reported by the research below: “3-year DFS data favor MH-IMRT, but the follow-up of 3.2 years median is short for prostate cancer; this difference may attenuate or shift with longer observation.”